What drugs does ALKERMES INC make?

ALKERMES INC has 4 FDA-approved drugs including LYBALVI, ARISTADA INITIO KIT, ARISTADA.

What therapeutic areas does ALKERMES INC focus on?

ALKERMES INC focuses primarily on Gastroenterology.

← Back

Data updated: Mar 29, 2026

ALKERMES INC

Gastroenterology

Specialty

ALKERMES INC is a specialty pharmaceutical company focused on Gastroenterology. Key products include LYBALVI.

2006

Since

Drugs

Trials

Approved (2yr)

Key Drugs

LYBALVI

olanzapine

CNS

5HT2 receptor 3 indications · 2021

ARISTADA INITIO KIT

aripiprazole lauroxil

CNS

5-HT1A receptor 1 indications · 2018

ARISTADA

aripiprazole lauroxil

CNS

5-HT1A receptor 1 indications · 2015

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

ARISTADA INITIO KIT 2025-01-22

SEC Filings ProEarly access

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Gastroenterology 100%

0 drugs Phase 1: 1

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

Pfizer big-pharma

Gastroenterology

Bristol-Myers Squibb big-pharma

ALKERMES INC

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (4)

Active (4)

Discontinued (0)

Company Info

ALKERMES INC

Set Alert

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (4)

Active (4)

Discontinued (0)

Company Info